News | June 05, 2014

Mercator Study to Evaluate the Use of Dexamethasone to Treat Peripheral Artery Disease

National 300-patient study to show effectiveness of adventitial therapy

June 5, 2014 — Mercator MedSystems is in the midst of its prospective, 300-patient, 30-site DANCE (Dexamethasone to the Adventitia to eNhance Clinical Efficacy) clinical trial to study a new therapeutic approach to treating peripheral artery disease (PAD). The trial enrolled its first patient in November 2013, and incorporates the use of Mercator MedSystems’ U.S. Food and Drug Administration (FDA)-cleared Micro-Infusion drug delivery system.

PAD occurs when fatty deposits collect in the peripheral arteries, restricting blood flow and oxygen to the legs and feet. Restricted blood flow results in difficulty with walking, an increased risk of heart attack or stroke, or amputation. Worldwide estimates published in The Lancet estimate the number of people suffering with PAD to be 202 million in 2010, including 17 million Americans.

The DANCE trial is being performed to corroborate results coming from the 20-patient DANCE Pilot, which was performed by Chris Owens, M.D., MSc, at the San Francisco VA Medical Center in California. The primary objective of the DANCE trial is to assess the reduction of inflammation and restenosis in patients with PAD by delivering dexamethasone, an anti-inflammatory steroid, to the adventitia, or outer tissue layer of a blood vessel. National co-principal investigators are Owens and Mahmood Razavi, M.D., of St. Joseph’s Heart and Vascular Center in Orange, Calif. The first procedure was performed by Stuart Harlin, M.D., FACS, at the Coastal Vascular and Interventional Center, in Pensacola, Fla.

Mercator Med Systems is attempting to improve the treatment of PAD by allowing clinicians to accurately and efficiently deliver small volumes of anti-inflammatory drug to the adventitia, which becomes highly inflamed during procedures to open the artery. “Until now, doctors have had to rely on indirect, non-specific methods of controlling inflammation from the inside of the blood vessel. We believe the ‘outside-in’ approach will potentially better target the localized injury caused by vascular procedures such as balloon angioplasty or atherectomy,” said Thomas M. Loarie, CEO of Mercator.

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Overlay Init